Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999
Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999
Anticytokine Antibodies in Beta Interferon-Trated MS Patients and the Need for Testing
Neurol 49:647-650, Pachner,A.R., 1997
The Quality-of-Life Effects of Interferon Beta-1b in MS
Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997
Guidelines for Physicians with Patients on IFNB-1b:The Use of an Assay for Neutralizing Antibodies (NAB)
Neurol 47:865-866, Paty,D.,et al, 1996
Interferon Beta in Multiple Sclerosis
BMJ 313:1159, 1157, 1195996., Richards,R.G., 1996
The Impact of New Pharmaceutical Agents on the Cost of Neurologic Care
Neurol 45:569-572, Gunderson,C.H., 1995
Practice Advisory on Selection of Patients with Multiple Sclerosis for Treatment with Betaseron
Neurol 44:1537-1540, Alter,M.,et al, 1994